Julie Krop - 23 Jun 2026 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: Director
Issuer ticker: AQST
Reported as of: 23 Jun 2026
Net transaction value: -$125,392
SEC form: 4
Accepted by SEC: 24 Jun 2026, 11:11:33 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas Zalewski, as Attorney-In-Fact

Key filing fact

Julie Krop filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 24 Jun 2026.

Key facts

This page summarizes Julie Krop's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2026, 11:11.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: -$125,392.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001643127 Primary reporting owner

Krop Julie

Relationship: Director
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Thomas Zalewski, as Attorney-In-Fact
Signature date: 24 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Options Exercise

Transaction value
Shares: +25,000
Change %
Price: $0.7132^*
Shares after: 25,000
Date: 23 Jun 2026
Ownership: Direct
Footnotes: F1

AQST transaction

Common Stock

Sale

Transaction value: $125,392
Shares: -25,000
Change %: -100%
Price: $5.02
Shares after: 0
Date: 23 Jun 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Non-Qualified Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -25,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 23 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $0.7132
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.

Footnote F2

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.

Footnote F3

This option was granted on June 22, 2022 and is fully vested.